Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Veracyte

Biotech & Life Sciences · San Francisco, United States · Founded 2008 · IPO 2013 Unicorn

Diagnostics for cancer

Valuation
$2.25B
Market cap · May/2026
Revenue
$516M
Latest reported FY
EBITDA
$145M
Latest reported FY

Investors

6 investors on Veracyte's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 6 investors entered at this stage
TPG Biotech
Kleiner Perkins
Versant Ventures
GE Ventures
TPG
Domain Associates

Global footprint

Where Veracyte has talent and traffic

AI talent share
2.0% of workforce is AI talent
(14 of 701 staff)
Core AI10.14%
Other AI131.85%
Non-AI workforce68798%
Workforce by country
13 countries with
team presence
🇺🇸 United States77.5%
🇫🇷 France15.3%
🇮🇱 Israel2.6%
🇪🇸 Spain1%
🇩🇪 Germany0.8%
Top 5 of 13 shown
Web traffic by country
81K monthly visits
across markets
🇺🇸 United States83.7%
🇮🇳 India6.4%
🇬🇧 United Kingdom1.7%
🇨🇦 Canada1.7%
🏳️ Russian Federation1.7%
Top 5 markets shown

Patent intelligence

$35M patent portfolio · 38 active families

Estimated portfolio value
$35M
1.5% of market cap · 1086.7× the top peer Sema4 ($32k)
38 active patent families
Where Veracyte innovates PathologyOncologyBiologyCancer researchInternal medicine

Where Veracyte concentrates vs peers

Each axis is a top-10 topic across Veracyte and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Veracyte's 4 investments and acquisitions.

Every disclosed deal where Veracyte appeared as a backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Veracyte's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Veracyte deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Veracyte's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Veracyte

        An AI-synthesized read of the highest-engagement posts about Veracyte on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Veracyte on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.